1. Home
  2. ASMB vs CGO Comparison

ASMB vs CGO Comparison

Compare ASMB & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • CGO
  • Stock Information
  • Founded
  • ASMB 2005
  • CGO 2004
  • Country
  • ASMB United States
  • CGO United States
  • Employees
  • ASMB N/A
  • CGO N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • CGO Investment Managers
  • Sector
  • ASMB Health Care
  • CGO Finance
  • Exchange
  • ASMB Nasdaq
  • CGO Nasdaq
  • Market Cap
  • ASMB 97.8M
  • CGO 114.2M
  • IPO Year
  • ASMB 2010
  • CGO N/A
  • Fundamental
  • Price
  • ASMB $15.21
  • CGO $11.66
  • Analyst Decision
  • ASMB Buy
  • CGO
  • Analyst Count
  • ASMB 2
  • CGO 0
  • Target Price
  • ASMB $35.00
  • CGO N/A
  • AVG Volume (30 Days)
  • ASMB 42.2K
  • CGO 34.7K
  • Earning Date
  • ASMB 11-07-2024
  • CGO 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • CGO 9.25%
  • EPS Growth
  • ASMB N/A
  • CGO N/A
  • EPS
  • ASMB N/A
  • CGO N/A
  • Revenue
  • ASMB $28,326,000.00
  • CGO N/A
  • Revenue This Year
  • ASMB $282.16
  • CGO N/A
  • Revenue Next Year
  • ASMB N/A
  • CGO N/A
  • P/E Ratio
  • ASMB N/A
  • CGO N/A
  • Revenue Growth
  • ASMB N/A
  • CGO N/A
  • 52 Week Low
  • ASMB $9.12
  • CGO $7.90
  • 52 Week High
  • ASMB $19.93
  • CGO $10.93
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 46.95
  • CGO 40.91
  • Support Level
  • ASMB $13.20
  • CGO $11.52
  • Resistance Level
  • ASMB $16.75
  • CGO $11.84
  • Average True Range (ATR)
  • ASMB 1.05
  • CGO 0.19
  • MACD
  • ASMB -0.08
  • CGO -0.03
  • Stochastic Oscillator
  • ASMB 53.03
  • CGO 22.13

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About CGO Calamos Global Total Return Fund

Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.

Share on Social Networks: